CircPTK2/PABPC1/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer

Meng, Xiangui; Xu, Wen; Sun, Jiayin; Li, Weiquan; Hu, Yuan; Yu, Tiexi; Zhang, Xiaoping; Dong, Wei

doi:10.1016/j.canlet.2022.216023

Cited by 53 publications

(21 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibodies used in Western blot, IHC, and IF were as follows: anti‐LY96 (Proteintech, 1:1000 for WB, 1:200 for IHC, 1:100 for IF), anti‐CD206 (Proteintech, 1:100 for IF), anti‐GAPDH (Abclonal, 1:10000 for WB) and anti‐β‐actin (Abclonal, 1:10000 for WB). All procedures were consistent with what was described earlier 53 …”

Section: Methodsmentioning

confidence: 99%

Gene LY96 is an M2 macrophage‐related biomarker and is associated with immunosuppression in renal cell carcinoma

Li,

Meng,

et al. 2023

MedComm – Oncology

Self Cite

View full text Add to dashboard Cite

Lymphocyte Antigen 96 (LY96) was identified as an oncogene in several tumors. However, its role in renal cancer has not been explored. In the study, LY96 is identified abnormally expressed using several public kidney cancer sequencing data. The expression level of LY96 is validated using paired clinical samples. Survival analyses and ROC curves are used to examine its prognostic and diagnostic value. Gene sets enrichment analyses (GSEA) show LY96 might influence immune processes. Then immune infiltration analyses results suggest that LY96 is positively correlated with M2 macrophages infiltration in RCC. Single‐cell data are used to verify its association with macrophages. Moreover, LY96 is positively with various immune scores and might affect the efficacy of immunotherapy. Drug screening results show LY96 might be the target of vemurafenib and etoposide. Further experiments confirm the spatial co‐localization of LY96 and M2, and knocking down LY96 can inhibit M2 polarization. Cell viability experiments indicate that knocking down LY96 would result in a decrease in the resistance of M2 macrophages to etoposide. The study shows LY96 could act as an unfavorable biomarker for RCC and possibly contribute to cancer progression by promoting the infiltration of M2 macrophage. LY96 could be a novel therapeutic target for RCC.

show abstract

Section: Methodsmentioning

confidence: 99%

Gene LY96 is an M2 macrophage‐related biomarker and is associated with immunosuppression in renal cell carcinoma

Li,

Meng,

et al. 2023

MedComm – Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, ferroptosis is also proposed as a process of autophagylysosomal cell death. LncRNA HEPFAL was found to increase the sensitivity of erastin-induced ferroptosis in hepatocellular carcinoma, and induce ubiquitination of SLC7A11 and decrease its expression by reducing the stability of SLC7A11 protein [7]. The voltage-dependent anion channel (VDAC)-mediated mitochondria dysfunction is necessary for erastin-induced ferroptosis and VDAC3 can act as a directly target of erastin [37].…”

Section: Regulation Of Frlncrnas In Urologic Cancers By Protein Levelsmentioning

confidence: 99%

“…Previous studies have suggested that lncRNAs induce or inhibit ferroptosis of cancer cells in few malignancies including gastric, hepatocellular, and lung cancer [5][6][7]. Recently, it has been identified that few ferroptosis-related lncRNAs (frlncRNAs) regulate the incidence and progression of urologic malignancies including prostate cancer (PCa), kidney cancer, and bladder cancer (BCa).…”

Section: Introductionmentioning

confidence: 99%

The Roles of Ferroptosis-related Long Non-coding RNAs in Urologic Cancers

Xie

Qin

et al. 2023

ann urol oncol

View full text Add to dashboard Cite

Ferroptosis is a type of programmed cell death that has been recent topic of interest in cancer therapy. Growing evidence indicates that long noncoding RNAs (lncRNAs) are involved in ferroptosis and associated with the incidence and progression of cancer. However, the relationship between lncRNA and ferroptosis in urologic cancers has not been fully elucidated. In this review, we summarize ferroptosis-related lncRNAs (frlncRNAs) in urologic cancers. Studies indicate that frlncRNAs are associated with cancer metabolism, tumor microenvironment, and immune cell infiltration. In addition, frlncRNAs could regulate ferroptosis related genes both at the mRNA and protein level. Therefore, a deep understanding of the roles of frlncRNAs in urologic cancers occurrence and progression will provide novel information for the development of anticancer therapies.

show abstract

“…35 Meng et al identified that circ_PTK2 promoted EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer via modulate PABPC1and SETDB1 expression. 36 Long-standing evidence suggested that circ_NRIP1 acted as oncogenes in various cancers including cervical cancer, ovarian cancer, nasopharyngeal carcinoma, papillary thyroid carcinoma, osteosarcoma, and so on. [37][38][39][40][41] However, the specific roles of circ_NRIP1 in BTC remain unclear.…”

Section: Akt2 Was the Downstream Gene Of Mir-515-5pmentioning

confidence: 99%

Circular RNA nuclear receptor interacting protein 1 promoted biliary tract cancer epithelial‐mesenchymal transition and stemness by regulating the miR‐515‐5p/AKT2 axis and PI3K/AKT/mTOR signaling pathway

Gào

Han

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

Biliary tract cancer (BTC) is a devastating malignancy that is notoriously difficult to diagnose and is associated with high mortality. Circular RNA (circRNA) is a class of endogenous non‐coding RNA which has been regarded as the key regulator of tumor initiation and progression, including BTC. Circular RNA nuclear receptor interacting protein 1 (circ_NRIP1), as a circular RNA, is abnormally expressed in many human tumors and exhibits diverse functions in cancer progression. However, its biological significance in BTC has not been thoroughly investigated. In this research, we elucidated that circ_NRIP1 was notably overexpressed in both BTC tissues and cells. We further established a correlation between circ_NRIP1 expression and clinicopathological features in BTC patients, highlighting its clinical relevance. Through functional assays, we observed that knockdown of circ_NRIP1 significantly inhibited tumor cell proliferation, invasion, stemness maintenance, and epithelial‐mesenchymal transition, indicating its active involvement in promoting BTC progression. Additionally, it attenuated growth of xenograft and metastasis models. Mechanically, we revealed that circ_NRIP1 served as the competing endogenous RNA to sequester miR‐515‐5p through complementary base pairing mechanism, thereby upregulated AKT2 expression and indirectly activated PI3K/AKT/mTOR signaling pathway. Generally, targeting the circ_NRIP1/miR‐515‐5p/AKT2 axis and aberrant activation of the PI3K/AKT/mTOR pathway may hold promising therapeutic strategies for BTC. Our research contributes to a better understanding of the underlying biological basis of BTC and paves the way for the development of innovative treatment approaches.

show abstract

CircPTK2/PABPC1/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer

Cited by 53 publications

References 56 publications

Gene LY96 is an M2 macrophage‐related biomarker and is associated with immunosuppression in renal cell carcinoma

Gene LY96 is an M2 macrophage‐related biomarker and is associated with immunosuppression in renal cell carcinoma

The Roles of Ferroptosis-related Long Non-coding RNAs in Urologic Cancers

Circular RNA nuclear receptor interacting protein 1 promoted biliary tract cancer epithelial‐mesenchymal transition and stemness by regulating the miR‐515‐5p/AKT2 axis and PI3K/AKT/mTOR signaling pathway

Contact Info

Product

Resources

About